Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-EBQ-guided obesity medication selection trial
ACTRN12622000703707Phase 4Not yet recruiting
- Sponsor
- Auckland District Health Board
- Start
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of naltrexone + bupropion, phentermine and liraglutide in obesity (7 arms), sponsored by Auckland District Health Board. Primary endpoints: Percent weight loss from baseline and Percent change in body mass index from baseline. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12622000703707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000703707.